The Public Health Agency of Canada (PHAC) last week reported an increase in antimicrobial-resistant gonococcal (AMR-GC) infections, including a near doubling of cases showing resistance or decreased susceptibility to two different antimicrobials.
The Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea (ESAG) report summarizes data on 3,377 gonorrhea cases submitted for analysis in four Canadian provinces (Alberta, Manitoba, Novia Scotia, and the Northwest Territories) from 2018 through 2021. Most patients (80.2%) were male, of which an average of 55.5% were among men who have sex with men (MSM).
From 2018 through 2020, the prevalence of AMR-GC (as indicated by resistance to at least one antibiotic) was stable, but it increased from 69.3% in 2020 to 77.4% in 2021, while GC cultures demonstrating resistance or decreased susceptibility to two different antimicrobials rose from 24.8% to 44.5%. In 2021, the AMR-GC burden was highest among MSM (85.2% of isolated cultures were resistant to at least one antimicrobial), followed by heterosexual men (73.5%) and women (66.7%).
Recommended regimen remains effective
Of tested antimicrobials, resistance to ciprofloxacin was most prevalent, rising from 46.6% of cases in 2020 to 63.1% in 2021. Resistance to ciprofloxacin and tetracycline was high among all sexual behavior groups but highest among MSM. But no cases demonstrating combined resistance to azithromycin and ceftriaxone or cefixime (the gonorrhea treatment regimens recommended by PHAC) were reported. Decreased susceptibility to ceftriaxone or cefixime was detected in one case each in 2018, 2020, and 2021, and in three cases in 2019.
Fourteen cases were reported by public health authorities as treatment failures, but none demonstrated resistance or decreased susceptibility to prescribed treatment regimens.
PHAC says that, as gonorrhea cases rise across Canada and resistance continues to evolve, it's hoping to recruit additional ESAG sites to collect more representative data.
"The continuous monitoring of AMR-GC patterns via surveillance is of paramount importance to ensure the effectiveness of the recommended antimicrobials to treat GC infection," the agency said. "ESAG can play an important role in assessing and monitoring the effectiveness of GC treatment options and for the success of Canadian initiatives to combat AMR-GC."